A Single-Centre, Single-Blind, Randomised, Placebo-Controlled, Single-Dose Phase I Study to Assess the Safety, Tolerability and Pharmacokinetics After Ascending Intravenous Doses of AZD1305 in Helahty Male Volunteers.
Phase of Trial: Phase I
Latest Information Update: 01 Dec 2010
At a glance
- Drugs AZD 1305 (Primary)
- Indications Arrhythmias; Atrial fibrillation
- Focus Adverse reactions
- 17 Aug 2008 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 25 Jun 2008 New trial record.